Jiangsu Yahong Meditech Co., Ltd. 688176.SS Stock
Jiangsu Yahong Meditech Co., Ltd. Price Chart
Jiangsu Yahong Meditech Co., Ltd. 688176.SS Financial and Trading Overview
Jiangsu Yahong Meditech Co., Ltd. stock price | 6.1 CNY |
Previous Close | 11.21 CNY |
Open | 11.27 CNY |
Bid | 11.12 CNY x N/A |
Ask | 11.14 CNY x N/A |
Day's Range | 11.11 - 11.43 CNY |
52 Week Range | 10.01 - 18.36 CNY |
Volume | 1.92M CNY |
Avg. Volume | 4.73M CNY |
Market Cap | 6.34B CNY |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.61 CNY |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 21.13 CNY |
688176.SS Valuation Measures
Enterprise Value | 3.83B CNY |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 159176.28 |
Price/Book (mrq) | 2.3366253 |
Enterprise Value/Revenue | 96103.05 |
Enterprise Value/EBITDA | -11.034 |
Trading Information
Jiangsu Yahong Meditech Co., Ltd. Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | -10.46% |
S&P500 52-Week Change | 20.43% |
52 Week High | 18.36 CNY |
52 Week Low | 10.01 CNY |
50-Day Moving Average | 14.82 CNY |
200-Day Moving Average | 13.25 CNY |
688176.SS Share Statistics
Avg. Volume (3 month) | 4.73M CNY |
Avg. Daily Volume (10-Days) | 5.62M CNY |
Shares Outstanding | 570M |
Float | 358.51M |
Short Ratio | N/A |
% Held by Insiders | 45.16% |
% Held by Institutions | 6.56% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -881919.10% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -7.51% |
Return on Equity (ttm) | -9.23% |
Income Statement
Revenue (ttm) | 39.82K CNY |
Revenue Per Share (ttm) | 0 CNY |
Quarterly Revenue Growth (yoy) | 150.00% |
Gross Profit (ttm) | -1807760 CNY |
EBITDA | -346826080 CNY |
Net Income Avi to Common (ttm) | -262233968 CNY |
Diluted EPS (ttm) | -0.45 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 2.58B CNY |
Total Cash Per Share (mrq) | 4.52 CNY |
Total Debt (mrq) | 19.32M CNY |
Total Debt/Equity (mrq) | 0.71 CNY |
Current Ratio (mrq) | 35.902 |
Book Value Per Share (mrq) | 4.759 |
Cash Flow Statement
Operating Cash Flow (ttm) | -249595296 CNY |
Levered Free Cash Flow (ttm) | -284190080 CNY |
Profile of Jiangsu Yahong Meditech Co., Ltd.
Country | China |
State | N/A |
City | Shanghai |
Address | Building B, Qiantan World Trade Center |
ZIP | 200126 |
Phone | 86 21 6858 3863 |
Website | https://www.asieris.cn |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 231 |
Jiangsu Yahong Meditech Co., Ltd. engages in the research and development, production, and commercialization of drugs for genitourinary system tumors and other diseases in China and internationally. Its pipeline includes APL-1202, an anti-tumor drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; APL-1501, an oral MetAP inhibitor that is in Phase I clinical trial for the treatment of urinary system tumors and drug-resistant urinary tract infections; APL-1706, an agent drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; and APL-1702, a photodynamic therapy product that is in Phase III clinical trial for the treatment of cervical high-grade squamous intraepithelial lesions of the cervix caused by infection of HPV subtypes. In addition, it develops targeted protein degraders which are in preclinical stage comprising ASN-1764 for the treatment of triple negative breast cancer; ASN-1780 for the treatment of metastatic castration-resistant prostate cancer; and APL-1901 for the treatment of ER positive breast cancer. Further, the company develops APL-1401 to treat moderately to severely active ulcerative colitis; and ASN-1733 to treat acinetobacter baumannii infection. Jiangsu Yahong Meditech Co., Ltd. was founded in 2010 and is based in Shanghai, China.
Q&A For Jiangsu Yahong Meditech Co., Ltd. Stock
What is a current 688176.SS stock price?
Jiangsu Yahong Meditech Co., Ltd. 688176.SS stock price today per share is 6.1 CNY.
How to purchase Jiangsu Yahong Meditech Co., Ltd. stock?
You can buy 688176.SS shares on the Shanghai exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Jiangsu Yahong Meditech Co., Ltd.?
The stock symbol or ticker of Jiangsu Yahong Meditech Co., Ltd. is 688176.SS.
Which industry does the Jiangsu Yahong Meditech Co., Ltd. company belong to?
The Jiangsu Yahong Meditech Co., Ltd. industry is Drug Manufacturers-General.
How many shares does Jiangsu Yahong Meditech Co., Ltd. have in circulation?
The max supply of Jiangsu Yahong Meditech Co., Ltd. shares is 570M.
What is Jiangsu Yahong Meditech Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Jiangsu Yahong Meditech Co., Ltd. PE Ratio is now.
What was Jiangsu Yahong Meditech Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Jiangsu Yahong Meditech Co., Ltd. EPS is -0.61 CNY over the trailing 12 months.
Which sector does the Jiangsu Yahong Meditech Co., Ltd. company belong to?
The Jiangsu Yahong Meditech Co., Ltd. sector is Healthcare.